# US 9,434,784 B1 · Nucleic acids encodng anti-C5A antibodies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,434,784 B1
- Document ID: US9434784B1
- Status: Granted
- Kind: B1
- Application number: 15/161,893
- Filed: 2016-05-23
- Published: 2016-09-15
- Granted: 2016-09-06
- Earliest claimed: 2010-04-30
- Assignees: Alexion Pharmaceuticals, Inc.
- Applicants: Alexion Pharmaceuticals, Inc.
- Inventors: Russell P. Rother; Douglas L. Sheridan; Paul P. Tamburini; Yuchun Zhang
- Web page: https://patentgrep.com/patent/US9434784B1

## CPC

- C07K 16/18: against material from animals or humans
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/06: Antihyperlipidemics
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A61P 7/06: Antianaemics
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 11/16: Central respiratory analeptics
- A61P 13/02: of urine or of the urinary tract, e.g. urine acidifiers
- A61P 13/12: of the kidneys
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/04: Antibacterial agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 2039/505: {comprising antibodies}
- C07K 14/472: {Complement proteins, e.g. anaphylatoxin, C3a, C5a}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/31: multispecific
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/41: Glycosylation, sialylation, or fucosylation
- C07K 2317/51: Complete heavy chain or Fd fragment, i.e. VH + CH1
- C07K 2317/515: Complete light chain, i.e. VL + CL
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/567: Framework region [FR]
- C07K 2317/71: Decreased effector function due to an Fc-modification
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure relates to, inter alia, antibodies, or antigen-binding fragments thereof, that bind to C5a and to use of the antibodies in methods for treating or preventing complement-associated disorders such as, but not limited to, atypical hemolytic uremic syndrome, age-related macular degeneration, rheumatoid arthritis, sepsis, severe burn, antiphospho lipid syndrome, asthma, lupus nephritis, Goodpasture's syndrome, and chronic obstructive pulmonary disease.

## Claims

### Claim 1

A nucleic acid encoding complementarity determining regions (CDRs) of a heavy chain variable region of an antibody, or antigen-binding fragment thereof, that binds to human C5a, wherein the heavy chain variable region comprises the amino acid sequence depicted in SEQ ID NO:45.

### Claim 2

A nucleic acid encoding complementarity determining regions (CDRs) of a light chain variable region of an antibody, or antigen-binding fragment thereof, that binds to human C5a, wherein the light chain variable region comprises the amino acid sequence depicted in SEQ ID NO:42.

### Claim 3

A nucleic acid encoding complementarity determining regions (CDRs) of heavy and light chain variable regions of an antibody, or antigen-binding fragments thereof, that bind to human C5a, wherein the heavy and light chain variable regions comprise the amino acid sequences depicted in SEQ ID NOs:45 and 42, respectively.

### Claim 4

A nucleic acid encoding a heavy chain variable region of an antibody, or antigen-binding fragment thereof, that binds to human C5a, wherein the heavy chain variable region comprises the amino acid sequence depicted in SEQ ID NO:45.

### Claim 5

A nucleic acid encoding a light chain variable region of an antibody, or antigen-binding fragment thereof, that binds to human C5a, wherein the light chain variable region comprising the amino acid sequence depicted in SEQ ID NO:42.

### Claim 6

A nucleic acid encoding heavy and light chain variable regions of an antibody, or antigen-binding fragments thereof, that bind to human C5a, wherein the heavy and light chain variable regions comprise the amino acid sequences depicted in SEQ ID NOs:45 and 42, respectively.

### Claim 7

A nucleic acid encoding a heavy chain of an antibody, or antigen-binding fragment thereof, that binds to C5a, wherein the heavy chain comprises the amino acid sequence depicted in SEQ ID NO: 49.

### Claim 8

A nucleic acid encoding a light chain of an antibody, or antigen-binding fragment thereof, that binds to C5a, wherein the light chain comprises the amino acid sequence depicted in SEQ ID NO: 40.

### Claim 9

A nucleic acid encoding a heavy chain and a light chain of an antibody, or antigen-binding fragment thereof, that binds to human C5a, wherein the heavy chain comprises the amino acid sequence depicted in SEQ ID NO: 49 and the light chain comprises the amino acid sequence depicted in SEQ ID NO: 40.

### Claim 10 (depends on 1)

An expression vector comprising the nucleic acid according to claim 1.

### Claim 11 (depends on 10)

A cell comprising the expression vector according to claim 10.

### Claim 12 (depends on 2)

An expression vector comprising the nucleic acid according to claim 2.

### Claim 13 (depends on 12)

A cell comprising the expression vector according to claim 12.

### Claim 14 (depends on 3)

An expression vector comprising the nucleic acid according to claim 3.

### Claim 15 (depends on 14)

A cell comprising the expression vector according to claim 14.

### Claim 16 (depends on 4)

An expression vector comprising the nucleic acid according to claim 4.

### Claim 17 (depends on 16)

A cell comprising the expression vector according to claim 16.

### Claim 18 (depends on 5)

An expression vector comprising the nucleic acid according to claim 5.

### Claim 19 (depends on 18)

A cell comprising the expression vector according to claim 18.

### Claim 20 (depends on 6)

An expression vector comprising the nucleic acid according to claim 6.

### Claim 21 (depends on 20)

A cell comprising the expression vector according to claim 20.

### Claim 22 (depends on 7)

An expression vector comprising the nucleic acid according to claim 7.

### Claim 23 (depends on 22)

A cell comprising the expression vector according to claim 22.

### Claim 24 (depends on 8)

An expression vector comprising the nucleic acid according to claim 8.

### Claim 25 (depends on 24)

A cell comprising the expression vector according to claim 24.

### Claim 26 (depends on 9)

An expression vector comprising the nucleic acid according to claim 9.

### Claim 27 (depends on 26)

A cell comprising the expression vector according to claim 26.